Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Target Raised at Royal Bank Of Canada

03 Nov 2026, 15:13 by Danessa Lincoln · The Markets Daily

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) had its price objective hoisted by Royal Bank Of Canada from $296.00 to $305.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada‘s price objective suggests a potential upside of 32.42% from the stock’s current price.

A number of other equities analysts also recently issued reports on JAZZ. Truist Financial increased their target price on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Barclays lifted their price target on Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. Piper Sandler upped their price objective on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Finally, Citigroup initiated coverage on Jazz Pharmaceuticals in a report on Wednesday, September 30th. They issued a “buy” rating and a $325.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.70.

Get Our Latest Report on Jazz Pharmaceuticals

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded up $15.88 during midday trading on Tuesday, hitting $230.32. The stock had a trading volume of 215,950 shares, compared to its average volume of 927,309. The company has a market capitalization of $14.95 billion, a PE ratio of 15.70, a P/E/G ratio of 0.41 and a beta of 0.38. Jazz Pharmaceuticals has a 1 year low of $128.80 and a 1 year high of $266.38. The stock has a 50 day moving average price of $231.16 and a two-hundred day moving average price of $216.50. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating analysts’ consensus estimates of ($4.05) by $0.17. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter last year, the firm earned $8.13 earnings per share. The firm’s revenue was up 10.4% compared to the same quarter last year. As a group, equities analysts predict that Jazz Pharmaceuticals will post 10.87 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $250.13, for a total value of $1,500,780.00. Following the sale, the director owned 351,875 shares in the company, valued at $88,014,493.75. This represents a 1.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president directly owned 65,686 shares of the company’s stock, valued at $16,401,794.20. The trade was a 53.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 94,121 shares of company stock valued at $23,337,922. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Triumph Capital Management grew its stake in Jazz Pharmaceuticals by 2.0% in the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock worth $626,000 after acquiring an additional 52 shares during the period. XML Financial LLC raised its holdings in Jazz Pharmaceuticals by 1.1% in the 3rd quarter. XML Financial LLC now owns 6,559 shares of the specialty pharmaceutical company’s stock valued at $1,519,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. raised its holdings in Jazz Pharmaceuticals by 0.3% in the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after acquiring an additional 73 shares during the last quarter. Root Financial Partners LLC raised its holdings in Jazz Pharmaceuticals by 42.8% in the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after acquiring an additional 89 shares during the last quarter. Finally, Evergreen Capital Management LLC lifted its stake in shares of Jazz Pharmaceuticals by 4.2% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,250 shares of the specialty pharmaceutical company’s stock worth $521,000 after purchasing an additional 90 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

Positive Sentiment: Jazz reported third-quarter revenue of approximately $1.24 billion, up 10.4% year over year and above the roughly $1.21 billion analyst estimate. Adjusted loss of $3.88 per share was narrower than the consensus loss of $4.05. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Positive Sentiment: The company raised its fiscal 2026 revenue outlook to approximately $4.8 billion-$4.9 billion, above the $4.7 billion-$4.73 billion consensus range. The increased forecast signals continued confidence in commercial execution. Jazz 2026 Revenue Guidance
Positive Sentiment: Ziihera launched in first-line HER2-positive metastatic gastric and esophageal cancer, while management identified potential peak sales of $3 billion-$5 billion. Xywav revenue also grew 12%, with 425 net patient additions during the quarter. Ziihera Launch and Guidance
Neutral Sentiment: Jazz completed its Actio acquisition, adding the ABS-1230 epilepsy candidate to its rare-neurology portfolio. The company will also present Phase 3 ACTION and Phase 2 brain-cancer research at the Society for Neuro-Oncology meeting, offering potential future catalysts but no immediate revenue impact. Jazz Neuro-Oncology Research
Negative Sentiment: The quarter’s loss contrasts sharply with $8.13 per-share earnings a year earlier. Investors may also remain cautious about decelerating growth and acquisition-related charges associated with Actio, leaving the stock at a crossroads despite the improved outlook. Jazz Earnings and Guidance Analysis

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.